Effect of Virechana Karma on Metabolic Syndrome

Clinical Evaluation of Virechana Karma in the management of Metabolic Syndrome

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/06/008934

Enrollment

Registered

2017-06-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Obese patients, High BP, Dylipidemia

Interventions

Intervention1: Single Group A: 3 Days of Trikatu cap- twice a day 6 Days oral administration of ghritam -morning time upto- 500ml virechana Drug- Trivrita leham- 70 gm total duration -60 days ist 1

Eligibility

Inclusion criteria

Inclusion criteria: 1. Fasting Glucose > 100 mg/dl 2. Blood pressure > 130/85 mmHg 3. HDL-C 4. Waist Circumference >90 cm in men or >80 cm in women Patient fit for Virechana Procedure with signs and symptoms of Metabolic Syndrome

Exclusion criteria

Exclusion criteria: 1. Age group 60 years 2. Uncontrolled Diabetes Mellitus (Type 2) with complications such as Nephropathy 3. Uncontrolled Hypertension or with complications 4. Known Case of IHD, CHF and any other vascular Disorders

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of Virechana Karma in the management of Metabolic Syndrome Complete Remission : 100% relief Markedly Improved : 71% - 99% relief Moderately Improved : 41% - 70% relief Mildly Improved : 16% - 40 % relief Unchanged : 0% - 15% relief Worsened : 0% Timepoint: 2 months	—

Secondary

Measure	Time frame
Exacerbation in sign and symptomsTimepoint: 1 month	—

Countries

India

Contacts

Public ContactNidhi Chaudhary

Rishikul Campus, Uttarakhand Ayurved University, Haridwar

nidhi.chaudhary648@gmail.com9761008284

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026